October 19, 2018
Ayumi Pharmaceutical is missing out on a big opportunity. Failing to capitalize on stronger-than-expected demand for Japan’s first and only Enbrel (etanercept) biosimilar it launched in May, the company is now asking medical institutions to stop its new prescriptions, while...read more